Detalles de la búsqueda
1.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156585
2.
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
Pediatr Blood Cancer
; 66(8): e27809, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31144772
3.
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 19(2): 229-239, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29361469
4.
Use of External Control Cohorts in Pediatric Brain Tumor Clinical Trials.
J Clin Oncol
; 42(12): 1340-1343, 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38394473
5.
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
Clin Cancer Res
; 28(19): 4173-4177, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35679021
6.
Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 177: 120-142, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335782
7.
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials.
Neuro Oncol
; 23(2): 189-198, 2021 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33130879
8.
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.
Neuro Oncol
; 23(8): 1252-1260, 2021 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822177
9.
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Eur J Cancer
; 157: 198-213, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34536944
10.
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Eur J Cancer
; 139: 135-148, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32992153
11.
Pediatric Development of Molecularly Targeted Oncology Drugs.
Clin Pharmacol Ther
; 104(2): 384-389, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29226303
12.
18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.
Neurooncol Pract
; 5(1): 28-36, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29692922
13.
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
Clin Cancer Res
; 23(24): 7448-7453, 2017 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28774898
14.
FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma.
Clin Cancer Res
; 23(19): 5661-5665, 2017 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28179454
15.
Factor X Umuahia: a severe bleeding diathesis associated with a novel mutation.
Pediatr Blood Cancer
; 55(6): 1246, 2010 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20730886
16.
Novel chemical library screen identifies naturally occurring plant products that specifically disrupt glioblastoma-endothelial cell interactions.
Oncotarget
; 6(21): 18282-92, 2015 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26286961
17.
Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
Oncotarget
; 5(20): 9811-22, 2014 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25238146
18.
Opportunities and challenges for successful use of bevacizumab in pediatrics.
Front Oncol
; 3: 92, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23641361
Resultados
1 -
18
de 18
1
Próxima >
>>